RT Journal Article
T1 SEOM Clinical Guideline for gastrointestinal sarcomas (GIST) (2016)
A1 Poveda, A.
A1 Martinez, V.
A1 Serrano, C.
A1 Sevilla, I.
A1 Lecumberri, M. J.
A1 de Beveridge, R. D.
A1 Estival, A.
A1 Vicente, D.
A1 Rubio, J.
A1 Martin-Broto, J.
K1 GIST
K1 Imatinib
K1 Sunitinib
K1 Regorafenib
K1 Stromal tumors
K1 Adjuvant imatinib
K1 Randomized-trial
K1 Phase-iii
K1 Follow-up
K1 Kinase
K1 Risk
K1 Multicenter
K1 Sensitivity
K1 Recurrence
AB Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the digestive tract, and this disease has served as a paradigmatic model for successful rational development of targeted therapies. The introduction of tyrosine kinase inhibitors with activity against KIT/PDGFRA in both localized and advanced stages has remarkably improved the survival in a disease formerly deemed resistant to all systemic therapies. The Spanish Society of Medical Oncology (SEOM) guidelines provide a multidisciplinary and updated consensus for the diagnosis and treatment of GIST patients. We strongly encourage that the managing of these patients should be performed within multidisciplinary teams in reference centers.
PB Springer-verlag italia srl
SN 1699-048X
YR 2016
FD 2016-12-01
LK http://hdl.handle.net/10668/18651
UL http://hdl.handle.net/10668/18651
LA en
DS RISalud
RD Apr 8, 2025